Piper Sandler analyst David Westenberg lowered the firm’s price target on NeoGenomics (NEO) to $12 from $18 and keeps an Overweight rating on the shares. The firm updated the company’s model post the earnings report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics, Sherwin-Williams, Grab, Paccar, First Solar: Trending by Analysts
- NeoGenomics: Hold Rating Amid Mixed Performance and Uncertain MRD Pathway
- NeoGenomics price target lowered to $10 from $17 at Morgan Stanley
- NeoGenomics price target lowered to $12 from $17 at TD Cowen
- NeoGenomics price target lowered to $10 from $12 at BofA